- Home
- NBTX vs AMC Comparison
NBTX vs AMC Comparison
Compare NBTX & AMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- AMC
- Stock Information
- Founded
- NBTX 2003
- AMC 1920
- Country
- NBTX France
- AMC United States
- Employees
- NBTX N/A
- AMC N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- AMC Movies/Entertainment
- Sector
- NBTX Health Care
- AMC Consumer Discretionary
- Exchange
- NBTX Nasdaq
- AMC Nasdaq
- Market Cap
- NBTX 1.3B
- AMC 1.3B
- IPO Year
- NBTX 2020
- AMC 2013
- Fundamental
- Price
- NBTX $21.69
- AMC $2.20
- Analyst Decision
- NBTX Strong Buy
- AMC Hold
- Analyst Count
- NBTX 1
- AMC 6
- Target Price
- NBTX $8.00
- AMC $3.33
- AVG Volume (30 Days)
- NBTX 99.0K
- AMC 24.9M
- Earning Date
- NBTX 09-30-2025
- AMC 11-05-2025
- Dividend Yield
- NBTX N/A
- AMC N/A
- EPS Growth
- NBTX N/A
- AMC N/A
- EPS
- NBTX N/A
- AMC N/A
- Revenue
- NBTX $11,930,711.00
- AMC $4,867,000,000.00
- Revenue This Year
- NBTX N/A
- AMC $7.97
- Revenue Next Year
- NBTX $122.94
- AMC $6.77
- P/E Ratio
- NBTX N/A
- AMC N/A
- Revenue Growth
- NBTX N/A
- AMC 9.74
- 52 Week Low
- NBTX $2.76
- AMC $2.11
- 52 Week High
- NBTX $30.35
- AMC $5.56
- Technical
- Relative Strength Index (RSI)
- NBTX 53.91
- AMC 26.74
- Support Level
- NBTX $19.90
- AMC $2.36
- Resistance Level
- NBTX $23.56
- AMC $2.50
- Average True Range (ATR)
- NBTX 1.39
- AMC 0.11
- MACD
- NBTX 0.06
- AMC -0.03
- Stochastic Oscillator
- NBTX 69.36
- AMC 14.55
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.